Abstract
4650 Background: Except for non-melanoma skin cancer, prostate cancer (PrCA) is the most commonly diagnosed cancer among males, and the second leading cause of cancer-related deaths. To monitor cancer incidence, CDC funds cancer registries in 45 states and D.C. through the National Program of Cancer Registries (NPCR). Methods: Incidence data from 39 NPCR registries and five Surveillance, Epidemiology, and End Results (SEER) registries, and mortality data from CDC’s National Vital Statistics System were used to calculate rates. Cancer incidence data represent 92% of the U.S. population and mortality data represent 100%. Incidence and death rates, age-adjusted to the 2000 U.S. standard, were categorized by state, and expressed per 100,000 men. Aggregate incidence rates were calculated for all U.S. census regions except the South, and death rates were calculated for all regions (Northeast, West, Midwest, and South). Results: In 2001, PrCA incidence rates varied significantly by state, ranging from 119.2 to 213.5 per 100,000 men in Arizona and D.C., respectively. PrCA death rates also varied and ranged from 20.1 in Hawaii to 46.2 in D.C. PrCA incidence varied among the census regions, with incidence significantly higher in the Northeast region compared to the Midwest and West (p<0.0001), and the Midwest higher than the West (p<0.0001). PrCA death rates were significantly lower in the Northeast compared to the South (p=0.03), while death rates in the Northeast, Midwest, and South were significantly higher than in the West (p<0.0001). Conclusions: Data from the NPCR program are an excellent source of local, state, and regional cancer incidence information. When used in conjunction with mortality data, cancer control planners can measure cancer burden to improve and direct practices in their area. Men should periodically consult with their physicians regarding current practices for screening and controlling PrCA, and engage in informed decision making regarding their use. No significant financial relationships to disclose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.